Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 2
1957 4
1958 1
1962 2
1963 6
1964 2
1965 2
1966 2
1967 1
1968 2
1970 5
1971 2
1972 1
1975 1
1976 2
1977 1
1979 1
1981 3
1982 5
1983 5
1984 1
1985 5
1986 10
1987 10
1988 5
1989 11
1990 14
1991 10
1992 13
1993 5
1994 14
1995 21
1996 13
1997 19
1998 17
1999 16
2000 26
2001 22
2002 21
2003 28
2004 22
2005 38
2006 44
2007 33
2008 28
2009 33
2010 42
2011 54
2012 60
2013 53
2014 59
2015 48
2016 70
2017 70
2018 54
2019 51
2020 57
2021 49
Text availability
Article attribute
Article type
Publication date

Search Results

1,087 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: sugimoto n. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Wilke H, et al. Among authors: sugimoto n. Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17. Lancet Oncol. 2014. PMID: 25240821 Clinical Trial.
Turbulence Activates Platelet Biogenesis to Enable Clinical Scale Ex Vivo Production.
Ito Y, Nakamura S, Sugimoto N, Shigemori T, Kato Y, Ohno M, Sakuma S, Ito K, Kumon H, Hirose H, Okamoto H, Nogawa M, Iwasaki M, Kihara S, Fujio K, Matsumoto T, Higashi N, Hashimoto K, Sawaguchi A, Harimoto KI, Nakagawa M, Yamamoto T, Handa M, Watanabe N, Nishi E, Arai F, Nishimura S, Eto K. Ito Y, et al. Among authors: sugimoto n. Cell. 2018 Jul 26;174(3):636-648.e18. doi: 10.1016/j.cell.2018.06.011. Epub 2018 Jul 12. Cell. 2018. PMID: 30017246 Free article.
Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
Yokoyama T, Takehara K, Sugimoto N, Kaneko K, Fujimoto E, Okazawa-Sakai M, Okame S, Shiroyama Y, Yokoyama T, Teramoto N, Ohsumi S, Saito S, Imai K, Sugano K. Yokoyama T, et al. Among authors: sugimoto n. BMC Cancer. 2018 May 21;18(1):576. doi: 10.1186/s12885-018-4489-0. BMC Cancer. 2018. PMID: 29783979 Free PMC article. Review.
Retraction. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice.
Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, Takuwa N, Gonda K, Yamamoto Y, Ohkawa R, Nishiuchi T, Sugimoto N, Yatomi Y, Mitsumori K, Asano M, Kinoshita M, Takuwa Y. Wang F, et al. Among authors: sugimoto n. J Clin Invest. 2012 Mar;122(3):1131. doi: 10.1172/jci63366. J Clin Invest. 2012. PMID: 22482119 Free PMC article. No abstract available.
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N. Kato K, et al. Among authors: sugimoto n. Gastric Cancer. 2019 Mar;22(2):344-354. doi: 10.1007/s10120-018-0899-6. Epub 2018 Dec 1. Gastric Cancer. 2019. PMID: 30506519 Free PMC article. Clinical Trial.
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D, Taniguchi H, Sugimoto N, Tamura T, Nishina T, Hara H, Esaki T, Denda T, Sakamoto T, Okuda H, Satoh T, Tsushima T, Makiyama A, Tsuda T, Hosokawa A, Kuramochi H, Tokunaga S, Moriwaki T, Yasui H, Ishida H, Tsuji A, Otsu S, Shimokawa H, Baba E, Sato M, Matsumoto S, Ozaki Y, Shinozaki K, Tamagawa H, Goto M, Kadowaki S, Fujii H, Koh Y, Yamazaki K, Hironaka S, Kishimoto J, Boku N, Hyodo I, Muro K. Sakai D, et al. Among authors: sugimoto n. Eur J Cancer. 2020 Aug;135:11-21. doi: 10.1016/j.ejca.2020.04.014. Epub 2020 Jun 8. Eur J Cancer. 2020. PMID: 32526634 Clinical Trial.
1,087 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page